

Co-funded by the Health Programme of the European Union



# Challenges of treating frail patients in geriatric services

### Graziano Onder Università Cattolica del Sacro Cuore, Rome, IT

KONFERENCA: OBVLADOVANJE KRHKOSTI DANES ZA JUTRI CONFERENCE: FRAILTY MANAGEMENT TODAY FOR TOMORROW Kongresni center Brdo, November 22nd 2017

ADVANTAGE JA

Joint Action on Prevention of frailty 2017-2019

### The 'modern' patient (or... the frail and complex patient)

- Multimorbidity
  Multiple drugs
  Mysical function
  Cognitive status
  Physical function
  Affective status
  Social status
  Incontinence
  - Malnutrition
  - → Falls

FRAILTY

→ Osteoporosis

**Researchers** have largely shied away from the complexity of multiple chronic conditions - avoidance that results in expensive, potentially harmful care of unclear benefit.



Tinetti M. NEJM2011

### Multimorbidity

- Defined as ≥ 2 chronic diseases
- Prevalence ↑ with age (>60% of people aged ≥ 65 y with multimorbidity 'most common chronic condition')
- Impact on **clinical outcomes** and health care **costs**
- Multimorbidity also affects processes of care and may result in complex care needs
- The **traditional single-disease approach inadequate** for multimorbidity

## Epidemiology of multimorbidity and implications for health care, research, and medical education: a cross-sectional study



Vol 380 July 7, 2012



Frailty and multimorbidity overlap (pooled data from 9 studies; n=14704). Frailty was defined according to the CHS criteria and multimorbidity defined as 2+ diseases.



Onder G et al. In press



## Predictors of Rehospitalization within 30 Days after Discharge.

Table 3. Predictors of Rehospitalization within 30 Day	's aπer Discharge."
Variable	Hazard Ratio (95% Confidence Interval)
Hospital's ratio of observed to expected hospital- izations†	1.097 (1.096–1.098)
National rehospitalization rate for DRG†	1.268 (1.267-1.270)
No. of rehospitalizations since October 1, 2003	
0	1.00
1	1.378 (1.374–1.383)
2	1.752 (1.746–1.759)
≥3	2.504 (2.495-2.513)
Length of stay	
>2 times that expected for DRG	1.266 (1.261–1.272)
0.5–2 times that expected for DRG	1.00
<0.5 times that expected for DRG	0.875 (0.872-0.877)
Racet	
Black	1.057 (1.053-1.061)
Other	1.00
Disability	1.130 (1.119–1.141)
Engestage repol discoss	1.417 (1.409–1.425)
Receipt of Supplemental Security Income	1.117 (1.113–1.122)
Male sex	1.056 (1.053–1.059)
Age	
<55 yr	1.00
55–64 yr	0.983 (0.978–0.988)
65–69 yr	0.999 (0.989–1.009)
70–74 yr	1.023 (1.012-1.035)
75–79 yr	1.071 (1.059–1.084)
80–84 yr	1.101 (1.089–1.113)
85–89 yr	1.123 (1.111–1.136)
>89 yr	1.118 (1.105–1.131)

![](_page_6_Figure_2.jpeg)

19.6% rehospitalized within 30 days...50.2% of the patients who wererehospitalized within 30 days, were not seenby a physician

Jencks SF et al. N Engl J Med 2009;360:1418-1428.

# Care pathway for patients with multimorbidity or frailty

	First contact	<b>Clinical assessment</b>	Intervention
Definition	ening for inforbidity and frailty	Clinical assessment	Care of frailty or multimorbidity
How	Diseases count and frailty screening	Clinical judgement and risk stratification tools (for those with multimorbidity)	Multimorbidity care model or chronic care model
Who	GP or trained healthcare professional	GP	Clinical practice
When	Every contact the person may have with public health services	Once multimorbidity or frailty are identified	Once screened positively and the GP has certified the complexity of unmet clinical and non clinical needs

Onder G et al. Eur J Intern Med 2017

![](_page_7_Picture_3.jpeg)

## **Risk stratification/target identification**

- Older population might have different characteristics
- Benefits may vary depening on type of population
- Risk stratification tools might help to:
  - target intervention to most care demanding population
  - target intervention on people that can take a benefit (Impactability)

## A program to prevent functional decline in physically frail, elderly persons

![](_page_9_Figure_1.jpeg)

#### Gill TM et al. N Engl J Med 2002

## **Risk stratification/target identification**

- Older population might have different characteristics
- Benefits may vary depening on type of population
- Risk stratification tools might help to:
  - target intervention to most care demanding population
  - target intervention on people that can take a benefit (Impactability)
  - select a reasonable number of patients (sensitivity and specificity)

#### Multimorbidity overview

**NICE** Pathways

![](_page_11_Figure_2.jpeg)

### **Tools to screen and diagnose frailty**

- 1. CHS/Frailty criteria
- 2. Frailty Index of accumulative deficits (FI-CD)
- 3. Frailty Index from CGA
- 4. Study of Osteoporostic Fractures Index (SOF)
- 5. Edmonton Frailty Scale
- 6. FRAIL Index
- 7. Clinical Frailty Scale
- 8. MPI
- 9. Tilburg Frailty Index
- 10. Prisma-7

- 11. Groningen Frailty Indicator
- 12. Sharebrooke Postal Questionnaire
- 13. Gerontopole Frailty Screening tool
- 14. Kihon Check list
- 15. Inter-Frail
- 16. FiND
- 17. Physical Frailty and Sarcopenia

GE

- 18. FRAIL-NH
- 19. Frailty Trait Scale
- 20. SPPB
- 21. Gait Speed

## Frailty screening – Conclusions WP4 JA ADVANTAGE

• We recommend that all persons older than 70 years should be screened for frailty.

• ... we propose a range of instruments to pick first in a screening phase...

• The choice of the tool should be contextualized to practice priorities and characteristics.

Frailty measurements can be likened to 'horses for courses', wherein different frailty measurements are suited to different populations. Some are better for population-level frailty screening, whereas others are best suited for clinical screening, or for clinical assessment (Dent et al EJIM 2015)

# Care pathway for patients with multimorbidity or frailty

	First contact	<b>Clinical assessment</b>	Intervention
Definition	Screening <b>for</b> multimorbidity and frailty	c Assessment	Care of frailty or multimorbidity
How	Diseases count and frailty screening	Clinical judgement and risk stratification tools (for those with multimorbidity)	Multimorbidity care model or chronic care model
Who	GP or trained healthcare professional	GP	Clinical practice
When	Every contact the person may have with public health services	Once multimorbidity or frailty are identified	Once screened positively and the GP has certified the complexity of unmet clinical and non clinical needs

#### Onder G et al. Eur J Intern Med 2017

![](_page_14_Picture_3.jpeg)

Time to face the challenge of multimorbidity. A European perspective from the joint action on chronic diseases and promoting healthy ageing across the life cycle (JA-CHRODIS)

![](_page_15_Picture_1.jpeg)

Graziano Onder <sup>a,b,\*</sup>, Katie Palmer <sup>b</sup>, Rokas Navickas <sup>c,d</sup>, Elena Jurevičienė <sup>c</sup>, Federica Mammarella <sup>a,b</sup>, Mirela Strandzheva <sup>e</sup>, Piermannuccio Mannucci <sup>f</sup>, Sergio Pecorelli <sup>b</sup>, Alessandra Marengoni <sup>b,g</sup>, on behalf of the, Joint Action on Chronic Diseases and Promoting Healthy Ageing across the Life Cycle (JA-CHRODIS)

### Patients with MM at high risk (target for intervention):

- Disease patterns
- Low socioeconomical status
  - Low income
  - Poor social support
- Poor physical function
- Mental health problems
  - Depression
  - Cognitive impairment

Need of comprehensive assessment and intervention

> *Monographic issue Eur J Intern Med 2015*

![](_page_15_Picture_14.jpeg)

### CGA for older adults admitted to hospital

	No of events/total					
	Comprehensive geriatric assessment	Control		Mantel-Ha fixed or ratio (95	enszel ids % CI)	
Ward					, , ,	
Landefeld 1995 <sup>35</sup>	72/327	88/324	-		_	
Counsell 2000 <sup>26</sup>	237/767	269/764				
Rubenstein 1984 <sup>45</sup>	26/63	36/60				
Subtotal (95% CI)	335/1157	393/1148				
Test for heterogeneity: $\chi^2 =$	2.19, df=2, P=0.33, I <sup>2</sup> =9%					
Test for overall effect: z=2.	76, P=0.006					
Team						
McVey 1989 <sup>38</sup>	32/93	40/92	-	-		<u> </u>
Thomas 1993 <sup>51</sup>	17/68	23/64	-	-	_	
Subtotal (95% CI)	49/161	63/156				
Test for heterogeneity: $\chi^2 =$	0.08, df=1, P=0.78,   <sup>2</sup> =0%					
Test for overall effect: z=1.	84, P=0.07					
Total (95% CI)	384/1318	456/1304			-	
Test for heterogeneity: $\gamma^2 =$	2.81, df=4, P=0.59, $ ^2=0\%$	1999 - The State of State (The State of				
Test for overall effect: $7=3$	24. P=0.001		0.5	0.7	1	1.5
	,		Favours intervention	on		Favours

OR for death or deterioration

Test for subgroup differences:  $\chi^2=0.54$ , df=1, P=0.46,  $|^2=0\%$ 

Full text - FREE

BM

#### Ellis G BMJ 2011 Oct 27;343:d6553

	Costs		
	Intervention	Control	
Cohen 2002,22 US:			
Geriatric unit-usual care outpatient v usual care inpatient-usual care outpatient	\$36 592 (SD 1844)	\$38 624 (SD 2037)	
Geriatric unit-geriatric outpatient v usual care inpatient-geriatric outpatient	\$35 935 (SD 1829)	\$35 951 (SD 1827)	
Collard 1985, <sup>25</sup> US:			
Choate	\$4015.17 (SE 0.03)	\$4545.13 (SE 0.03)	
Symmes	\$3591.42 (SE 0.03)	\$4155.54 (SE 0.02)	
Fretwell 1990,27 US	\$3148 (SD 7210)	\$4163 (SD 18 406)	
Applegate 1990, <sup>19</sup> US:			
Geriatric unit (rehab diagnosis) v usual care (rehab diagnosis)	\$32 978 (SD 35 130)	\$18 409 (SD 16 555)	
Geriatric unit (medical/surgical diagnosis) v usual care (medical/surgical diagnosis)	\$25 846 (SD 29 628)	\$15 248 (SD 13 152)	
Asplund 2000, <sup>21</sup> Sweden (Swedish kroner)	10 800 (IQR 9300-12 300)	12 800 (IQR 11 500-14 100)	
Counsell 2000, <sup>26</sup> US	\$5640	\$5754	
Hogan 1987, <sup>30</sup> Canada	\$C98.36	\$C77.68	
Landefeld 1995, <sup>35</sup> US	\$6608	\$7240	
Nikolaus 1999, <sup>41</sup> Germany (deutschmark):			
Geriatric unit-early supported discharge	3 365 000 (\$1 922 400)	4 145 000 (\$2 368 300)	
Geriatric unit only	3 983 000 (\$2 276 600)	-	
Rubenstein 1984,45 US	\$22 597	\$27 826	
Naughton 1994,40 US	\$4525 (SD 5087)	\$6474 (SD 7000)	
White 1994, <sup>52</sup> US	\$23 906	\$45 189	

Many of the **hospital** costs seem to show a reduction in costs ... Some trials reported greater costs in the treatment group for hospitals. If **nursing** home costs are taken into consideration, the potential benefit of comprehensive geriatric assessment might be greater.

BMJ 2011;343:d6553

### Effect of Home Visits on Functional Impairment

![](_page_18_Figure_1.jpeg)

Risk Ratio (95% Confidence Interval)

2

10

Stuck A JAMA 2002;287:1022-1028. 🚟 JAMA

# Assessment and treatment of elderly patients with cancer

![](_page_19_Figure_1.jpeg)

Balducci L Surg Oncol. 2010

## Frailty assessment – Conclusions WP4 JA ADVANTAGE

...**the gold standard** for diagnosing the functional status of the person (that includes frailty status) **is the comprehensive geriatric assessment** (CGA). It is therefore important, when screening is positive, to perform a CGA and to diagnose frailty by the use of validated scales, derived from the CGA...

![](_page_20_Picture_2.jpeg)

# Care pathway for patients with multimorbidity or frailty

	First contact	<b>Clinical assessment</b>	Intervention
Definition	Screening for multimorbidity and frailty	Clinical assessment	frailty or atimorbidity
How	Diseases count and frailty screening	Clinical judgement and risk stratification tools (for those with multimorbidity)	Multimorbidity care model or chronic care model
Who	GP or trained healthcare professional	GP	Clinical practice
When	Every contact the person may have with public health services	Once multimorbidity or frailty are identified	Once screened positively and the GP has certified the complexity of unmet clinical and non clinical needs

Onder G et al. Eur J Intern Med 2017

![](_page_21_Picture_3.jpeg)

### How to organize the care?

Review (BMJ 2012 Sep 3;345:e5205) → Evidence on the care of patients with multimorbidity is limited...
 Interventions had mixed effects...

![](_page_22_Picture_2.jpeg)

## **Review of care pathways for Multimorbidity and Frailty**

Scientific literature review + field survey

- Programs varied in the target patient groups, implementation settings, number of included interventions, and number of chronic care model components
- Different components of the intervention were identified (comprehensive programs)
- Effectiveness of the programs rarely evaluated

![](_page_23_Picture_5.jpeg)

![](_page_23_Picture_6.jpeg)

Hopman et al. Health Policy. 2016

### **Good Clinical Practices**

![](_page_24_Picture_1.jpeg)

	POTKU, Finland	Clinic for Multimorbidity and Polypharmacy, Denmark	Strategy for Chronic Care Valencia Region, Spain
Main aim:	Improve patient- centredness	Substitution, support primary care	Improve delivery of integrated care
Target group:	Chronic patients	Chronic patients with more complex needs	Patients with 'highly complex needs'
Based in:	Primary care	Diagnostic clinic in hospital	Primary care + hospital care
Care model:	PC doctor/nurse teams, individual care plan	teams of specialists/others, 'one day'-service, treatment plan for care by PC doctor	Community nurse case manager + hospital nurse case manager, joint monitoring

## Develop a common model for multimorbidity management

### **Delivery system design**

- Comprehensive assessment
- Coordinated team
- Individualized care plans
- Case manager

#### **Decision support**

- Implementation of EBM
- Team training
- Consultation system

#### Self management

- Tailor Self-management
- Options for self management
- Shared decision making

### **Clinical information system**

- Electronic patients records
- Exchange patients infos
- Uniform coding
- Patient operated technology

### **Community resources**

- Access community resources
- Involvement of social network

Palmer K et al. Health policy 2017

![](_page_25_Picture_23.jpeg)

## Develop a common model for multimorbidity management

16 components identified

For each component:

- Description and aims
- Key characteristics
- Relevance to multimorbidity patients

The model derives from *expert opinion*. Its applicability should be tested in pilot actions

![](_page_26_Picture_7.jpeg)

![](_page_27_Picture_0.jpeg)

The CHRODIS PLUS Joint Action of the European Union supports Member States through cross-national initiatives identified in the JA-CHRODIS (2013-2016) to reduce the burden of chronic diseases. CHRODIS PLUS promotes the **implementation of policies and practices** with demonstrated success in closely monitored implementation experiences.

### **Assess outcomes**

![](_page_28_Picture_1.jpeg)

- Organize your practice
- Follow up and reassess
- Assess outcomes

![](_page_28_Picture_5.jpeg)

Assess and understand you own evidence

### **Good Clinical Practices**

![](_page_29_Picture_1.jpeg)

	Quality of care	Patient outcomes	Utilization / costs
POTKU, Finland	Patients with individual care plan more positive (PACIC). Care providers experience improved quality.		Use of primary care decreased (2012-2014), except phone calls to nurses.
Clinic for Multimorbidity and Polypharmacy, Denmark	Improved quality and coordination of care according to care providers involved		"The multimorbidity clinic results in a more efficient use of hospital resources."
Strategy for Chronic Care Valencia Region, Spain		Between 2011 and 2013 decrease of older people with polypharmacy of 34 300 (-10%).	In 2012-2014, > 200 000 patients with polypharmacy reviewed and 100 000 drug prescriptions changed, resulting in decrease of expenditures on drugs, from 19.5 million Euros in 2012 to 7.3 million in 2014.

### Conclusions

Challenge related to complexity of frail patients

- Key steps of geriatric practices:
- Screening  $\rightarrow$  site specific
- Assessment patients  $\rightarrow$  CGA
- Intervention  $\rightarrow$  integrated care model
- Assessment of outcomes

## www.advantageja.eu

Graziano Onder graziano.onder@unicatt.it